Trial Profile

A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 Results (n= 243) assessing baseline ctDNA levels were by mean tumor molecules .presented at the 116th Annual Meeting of the American Association for Cancer Research
25 Jan 2025 Results presented in the Natera media release Media Release.
25 Jan 2025 According to a Natera media release, company presented a poster highlighting data from the ALTAIR clinical trial at the American Society of Clinical Oncologys Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23-25, 2025 in San Francisco, CA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com